Phio Pharma initiates Phase Ib trial of melanoma treatment
Source: Clinical Trial Arena, April 2022
Phio Pharmaceuticals has initiated subject enrolment in the Phase Ib clinical trial of its lead programme, PH-762, to treat advanced melanoma.
The trial is being carried out at the Gustave Roussy Institute, the largest cancer centre in Europe.
It will assess the safety, tolerability, pharmacokinetics and anti-tumour activity of PH-762 in participants with advanced melanoma in a neoadjuvant setting.
READ THE ORIGINAL FULL ARTICLE